Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Celldex Therapeutics’s reported figures.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's EBIT?
- Celldex Therapeutics (CLDX) reported EBIT of -$80.62M in Q2 2026.
- How has Celldex Therapeutics's EBIT changed year-over-year?
- Celldex Therapeutics's EBIT decreased by 26.3% year-over-year, from -$63.86M to -$80.62M.
- What is the long-term trend for Celldex Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Celldex Therapeutics's EBIT has grown at a 41.7% compound annual growth rate (CAGR), from -$71.24M to -$287.37M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Celldex Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude